In the KEYNOTE-189 trial involving newly diagnosed metastatic nonsquamous NSCLC patients without EGFR/ALK mutations, chemoimmunotherapy with pembrolizumab, pemetrexed, and platinum-based chemotherapy resulted in a lower risk of death (HR: 0.60), improved 5-year survival (19.4% vs. 11.3%), and better disease control (HR: 0.50, 5-year PFS: 7.5% vs. 0.6%) compared to the placebo group. The gene discussed is ALK; the disease is non-small cell lung carcinoma.